Herantis Pharma releases update on timeline of its ongoing CDNF trial
Category: #health  By Nikita Chaurasia  Date: 2019-09-30
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Herantis Pharma releases update on timeline of its ongoing CDNF trial

Parkinson's disease (PD) is an incurable, progressive neurodegenerative disease which is caused by the death of dopaminergic neurons in the midbrain. With medication, motor symptoms can be treated but it is impossible to prevent the progression of this disease. Currently, numerous clinical trials are being carried out across the world to develop new treatments to slow down the progression of this disease in an efficient way.

Herantis Pharma Plc has reportedly released a new update regarding the timeline for its ongoing Phase 1-2 trial that examines its new drug candidate, CDNF, and neuroprotective factor, in patients who are suffering from Parkinson’s disease. 

According to the sources, the patient recruitment procedure has been completed. 17 patients have been implanted with a medical device which will be used for injecting CDNF. 

Sources cite that the trial will proceed further as per the scheduled timeline as is expected to finish patient visits by the last quarter (Q4) of 2019. The analysis and completion of the data for the study’s unblinding might be completed by the end of the first quarter (Q1) of 2020. Thus, Herantis is updating guidance on the topline data announcement of study from Q4 of this year to the Q1 of next year.

The main objective of this study is to evaluate the tolerability and safety of CDNF and the drug delivery device’s dosing efficiency. After completing the main study, the patients may continue with CDNF doses for another six months. The extension study would be followed by a follow-up study.

Pekka Simula, CEO of Herantis stated that the company’s first-in-human CDNF study is carried out in patients who are suffering from advanced Parkinson’s disease. Assessment of the safety criteria will depend on complete analysis. Moreover, it is vital to take enough time to interpret and prepare the trial results before proceeding with the unblinding of the study. 

The information regarding tolerability and safety will equip the company with fundamental details that are required to determine the future road map of this treatment.

Source Credit - http://herantis.com/release/herantis-pharma-plc-provides-update-on-timeline-for-ongoing-phase-1-2-cdnf-trial/#

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...